- Home
- GRRR vs IMAB Comparison
GRRR vs IMAB Comparison
Compare GRRR & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRRR
- IMAB
- Stock Information
- Founded
- GRRR 2001
- IMAB 2014
- Country
- GRRR United Kingdom
- IMAB United States
- Employees
- GRRR N/A
- IMAB N/A
- Industry
- GRRR Computer Software: Prepackaged Software
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- GRRR Technology
- IMAB Health Care
- Exchange
- GRRR Nasdaq
- IMAB Nasdaq
- Market Cap
- GRRR 391.9M
- IMAB 394.2M
- IPO Year
- GRRR N/A
- IMAB 2020
- Fundamental
- Price
- GRRR $16.77
- IMAB $6.56
- Analyst Decision
- GRRR Buy
- IMAB Strong Buy
- Analyst Count
- GRRR 1
- IMAB 6
- Target Price
- GRRR $18.00
- IMAB $7.17
- AVG Volume (30 Days)
- GRRR 2.0M
- IMAB 1.9M
- Earning Date
- GRRR 08-14-2025
- IMAB 11-02-2025
- Dividend Yield
- GRRR N/A
- IMAB N/A
- EPS Growth
- GRRR N/A
- IMAB N/A
- EPS
- GRRR N/A
- IMAB N/A
- Revenue
- GRRR $93,325,178.00
- IMAB N/A
- Revenue This Year
- GRRR $36.14
- IMAB N/A
- Revenue Next Year
- GRRR $27.83
- IMAB N/A
- P/E Ratio
- GRRR N/A
- IMAB N/A
- Revenue Growth
- GRRR 18.22
- IMAB N/A
- 52 Week Low
- GRRR $3.71
- IMAB $0.60
- 52 Week High
- GRRR $44.15
- IMAB $6.72
- Technical
- Relative Strength Index (RSI)
- GRRR 39.54
- IMAB 77.25
- Support Level
- GRRR $18.12
- IMAB $4.32
- Resistance Level
- GRRR $18.68
- IMAB $6.16
- Average True Range (ATR)
- GRRR 1.29
- IMAB 0.57
- MACD
- GRRR -0.34
- IMAB 0.26
- Stochastic Oscillator
- GRRR 2.57
- IMAB 93.22
About GRRR Gorilla Technology Group Inc.
Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).